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Abstract
Background: The economic burden of vertebral compression fractures (VCF) caused by osteoporosis was estimated
at 37 billion euros in the European Union in 2010. In addition, the incidence is expected to increase by 25% in
2025. The recommendations for the therapy of VCFs (conservative treatment versus cement augmentation
procedures) are controversial, what could be partly explained by the lack of standardized outcomes for measuring
the success of both treatments. Consensus on outcome parameters may improve the relevance of a study and for
further comparisons in meta-analyses. The aim of this study was to analyze outcome measures from frequently
cited randomized controlled trials (RCTs) about VCF treatments in order to provide guidance for future studies.
Material and methods: We carried out a systematic search of all implemented databases from 1973 to 2019 using
the Web of Science database. The terms “spine” and “random” were used for the search. We included: Level I RCTs,
conservative treatment or cement augmentation of osteoporotic vertebral fractures, cited ≥50 times. The outcome
parameters of each study were extracted and sorted according to the frequency of use.
Results: Nine studies met the inclusion criteria. In total, 23 different outcome parameters were used in the nine
analyzed studies. Overall, the five most frequently used outcome parameters (≥ 4 times used) were the visual
analogue scale (VAS) for pain (n = 9), European Quality of Life–5 Dimensions (EQ-5D; n = 4) and Roland–Morris
Disability Questionnaire (RMDQ, n = 4).
Conclusion: With our study, we demonstrated that a large inconsistency exists between outcome measures in
highly cited Level I studies of VCF treatment. Pain (VAS), followed by HrQoL (EQ-5D) and disability and function
(RMDQ), opioid use, and radiological outcome (kyphotic angle, VBH, and new VCFs) were the most commonly used
outcome parameters.
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Introduction
Osteoporosis is a systemic skeletal disease that is charac-
terized by a loss of bone density and microarchitecture
and a resulting increase in bone fragility and thus the
susceptibility to fractures [1]. The most common osteo-
porotic fractures are non-traumatic hip fractures
followed by vertebral compression fractures (VCF) and
forearm fractures [2]. In postmenopausal women, in par-
ticular, the incidence of osteoporotic VCF increases with
age. For example, the lifelong risk of a 50-year-old Cau-
casian woman suffering from VCF is 16% [3, 4]. The
consequence of this can be the loss of daily activities [5]
and an up to an eight-fold increase in mortality [6]. In
addition, the decrease in disability-adjusted life years
(DALY) due to osteoporotic VCFs even exceeds that of
common cancers [5].
Treatment of patients with osteoporotic VCFs is either
conservative or surgical. Conservative treatment consists
of pain relievers, early mobilization and radiological
follow-up examinations to check the stability of the frac-
ture. In contrast, surgical treatment mainly involves ce-
ment augmentation procedures of the fractured
vertebrae [7]. Technically, a distinction is made between
vertebroplasty (VP) and kyphoplasty (KP) [8]. While
both are minimally invasive and percutaneous proce-
dures, the difference, however, is that with KP the ce-
ment is applied into a cavity of the vertebral body (VB)
previously created by a balloon. In contrast, the VP does
not take this step. These two treatment strategies aim to
achieve short-, medium- and long-term pain control as
well as a reduction in disability, morbidity and mortality.
This must be accompanied by antiosteoporotic drug
therapy, as this is the basic intervention for patients with
osteoporotic fractures [9]. In addition, if the VB height is
not restored, spinal alignment may change, which is also
related to other comorbidities, such as the risk of subse-
quent pulmonary death [10].
Despite a large number of published studies, there is no
consensus on whether cement augmentation procedures
for VCFs are advantageous in terms of achieving the pre-
defined treatment goals compared to non-surgical treat-
ment [7, 11]. This is noteworthy considering the fact that
this treatment has been done frequently over the past 20
years. Although a majority of the published studies advo-
cate cement enlargement, many of these studies use a
retrospective study design and show no statistical signifi-
cance [11]. Furthermore, there is a large variation in out-
come parameters, which affects comparability between
these studies. These outcome parameters include Health-
Related Quality of Life (HRQoL), disability and function,
and the radiological result.
The increasing number of osteoporotic VCF requires
guidelines in clinical decision-making. To plan a Level I
clinical trial, selecting the appropriate outcome measures
is a challenging task. However, it is essential to carefully
select these parameters to demonstrate adequate effects
in clinical trials [12]. This systematic review aims to ex-
tract the outcome parameters from the most cited stud-
ies on VCF treatment to guide future study designs and
clinical decisions.
Materials and methods
We carried out a systematic review by following the PRIS
MA declaration (Preferred Reporting Items for Systematic
Reviews and Meta-Analysis) [13]. As this study is based
on public literature, it does not apply to ethical approval.
All articles on osteoporotic spinal fractures between
1973 and 2019 were identified in each journal (medical
and non-medical) using the Web of Science Core
Collection. Inclusion criteria were (1) treatment of
osteoporotic vertebral body fractures in humans with ce-
ment augmentation (VP or KP); (2) Level I randomized
controlled trials (RCT) based on the definition of the
“Oxford Center for Evidence-Based Medicine (CEBM)”
[14]; (3) more than 50 citations. Exclusion criteria were
(1) animal studies, spondyloarthritis, medical therapy,
exercise therapy, and traumatic osteoporosis; (2) non-
clinical studies, systematic reviews and meta-analyzes;
(3) fewer than 50 citations. A multi-step approach was
used to identify level 1 studies [14] with ≥50 total cita-
tions addressing VCF (Fig. 1). Five hundred and twenty-
four articles met the inclusion criteria. A further 513
papers were excluded based on the exclusion criteria
after studying the abstract.
Results
Nine studies, all published between 2009 and 2011, met
the inclusion criteria for this review (Fig. 1).
Of the included studies, three were published in gen-
eral medical journals (The New England Journal of
Medicine, Lancet), three in spine research related jour-
nals (Spine, Journal of Neurosurgery-Spine), one in a
radiological journal (the American Journal of Neuroradi-
ology), and two in osteoporosis/ bone research journals
(Osteoporosis International, Journal of Bone and Min-
eral Research).
Five studies came from Europe, two from Asia, one
from the USA, and one from Australia. The total num-
ber of citations was between 60 to 561 with a citation
density of 9 to 70 per year. One study was declared an
industry-sponsored trial [15]. The two studies with the
highest number of citations were published by Kallmes
et al. [16] and Buchbinder et al. [17] both in the New
England Journal of Medicine (NEJM) (Table 1).
Interventions performed
The following objectives were analysed in the included
studies: VP/KP versus conservative treatment (n = 5), VP
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versus sham procedures (n = 2), VP versus KP (n = 1), and
different cement formulations for KP (n = 1) (Table 1).
Outcome parameter
The absolute use of all outcome parameters was analyzed
regarding their type (pain, HRQol, function and disability,
radiographic imaging and others). In total, 23 different
outcome parameters were used in the nine analyzed stud-
ies. Ten different outcome parameters were used to
analyze the HRQol, five different parameters for radio-
graphic imaging, four for disability and function and one
for pain (Table 2, Table S1 of supplemental material).
Overall the five top used outcome parameters (≥ 4 times
used) were: Visual analogue scale (VAS-pain; n = 9),
Fig. 1 Selection process of studies. OF = Osteoporotic fracture; RCT = Randomized controlled trial
Table 1 Summary of overall citation and citation density of included studies






1. Kallmes et al. [16] NEJM 2009 VP vs Sham 561 70
2. Buchbinder et al. [17] NEJM 2009 VP vs Sham 554 69
3. Klazen et al. [18, 19] Lancet 2010 VP vs conservative 299 43
4. Rousing et al. [20] Spine 2010 VP vs conservative 104 15
5. Liu et al. [21] Osteoporosis International 2010 VP vs KP 102 15
6. Farrokhi et al. [22] Journal Neurosurgery Spine 2011 VP vs conservative 72 12
7. Boonen et al. [15] JBMR 2011 KP vs conservative 65 11
8. Blattert et al. [23] Spine 2009 KP (CaP vs PMMA) 62 8
9. Klazen et al. [19] American Journal of Neuroradiology 2010 VP vs conservative 60 9
NEJM = New England Journal of Medicine, JBMR = Journal of Bone and Mineral Research, VP = Vertebroplasty, KP = Kyphoplasty, CaP = Calcium
phosphate, PMMA = polymethylmethacrylate.
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European Quality of Life–5 Dimensions (EQ-5D Score;
n = 4) and Roland–Morris Disability Questionnaire
(RMDQ; n = 4) (Table 2).
Pain
A Visual or Numeric Rating Scale scale (VAS and NRS
respectively) is an easy and widely used instrument for
pain measurement [24, 25]. Five of the nine studies de-
fined pain as their primary outcome (Table 2). Further-
more, the pain was measured in every study at least at
baseline. In the short term, four of nine studies assessed
pain after 1 week. The most frequently used long term
time points were 3, 6, and 12 months (Fig. 2, Table S1
additional files).
Other measures of pain were the Pain Frequency and
Pain Bothersomeness Indices each measured on a 0 to 4-
point scale, with higher scores indicating more severe
pain [11]. This questionnaire was used by only one study
at baseline and one month follow up, making it the least
frequently used questionnaire (Fig. 4, Table S1 additional
file).
Health-related quality of life (HRQoL)
Numerous questionnaires are available for recording
HRQoL. In the nine studies analyzed, a total of five dif-
ferent instruments were used.
The European Quality of Life–5 Dimensions (EQ–5D)
scale (scale from 0 to 1, where 1 indicates perfect health)
is a commonly used questionnaire that is also free of
charge [26–28]. Five of the nine studies collected the
EQ-5D at baseline, while four studies had also collected
follow-up data (Fig. 3, Table S1 additional file).
The Short Form 36 General Health Survey (SF 36) [29,
30] is also a well-known and commonly used measure to
assess HRQoL. It averages the items of each subscale to
generate a score ranging from 0 to 100, with a lower
score representing greater disability [31]. In addition, the
SF-36 has a physical and mental component score (PCS
and MCS, respectively). Overall, the SF-36 was obtained
Table 2 Publications included in the analysis according to the inclusion criteria
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Citation density (Citations/ year); AQoL = The Assessment of Quality of Life; cons. = conservative treatment; JBMR = Journal of Bone and Mineral Research; KA =
Kyphotic angle; KP = kyphoplasty; MRI = Magnetic Resonance Imaging; NEJM = The New England Journal of Medicine; QUALEFFO = Questionnaire of the European
Foundation for Osteoporosis; VCF = Vertebral compression fracture; VP = Vertebroplastie; DPQ = Dallas Pain Questionnaire; EQ-5D = European Quality of Life–5
Dimensions; MCS =Mental component score;mmSE =Mini-Mental State Examination; ODI = Oswestry Disability Index; PCS = Physical component score; RMDQ =
Roland–Morris Disability Questionnaire; SF 36 = Short Form 36 General Health Survey; SI = Sagittal index; VBH = Vertebral body height.
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at baseline and follow-up in three of the nine RCTs, but
at different time points. (Fig. 3, Table S1 additional file).
The Questionnaire of the European Foundation for
Osteoporosis (QUALEFFO) is a 41-item questionnaire
specifically related to vertebral fractures and osteopor-
osis (scores range from 0 to 100, with lower scores indi-
cating better quality of life) [32]. This questionnaire was
used in two clinical trials [17, 18] (Fig. 3, Table S1 add-
itional file).
There were additionally two other questionnaires used
to measure HRQoL. One is the Assessment of Quality of
Life (AQoL) questionnaire, which is a well-validated in-
strument sensitive to changes in the elderly and frail
(scores range from 0 to 1, with 1 indicating perfect
health) [33]. The other one was the Study of Osteoporotic
Fractures-Activities of Daily Living (SOF-ADL) question-
naire, an easily obtained index to assess frailty [34].
However, these two questionnaires were only collected
by one study, and the SOF-ADL was only collected once
at baseline (Fig. 3, Table S1 additional file).
Disability and function
Four different instruments were used to assess disability
and function in the nine studies analyzed.
The Roland-Morris Disability Questionnaire (RMDQ)
is a widely used measure to assess health status in low
Fig. 2 Overview of the time points at which pain assessment was collected using the Visual Analogue Scale (VAS) in the nine studies analyzed
Fig. 3 Overview of the time points at which the different questionnaires from the health-related quality of life (HRQoL) category were evaluated
in the nine studies analyzed. QUALEFO = Questionnaire of the European Foundation for Osteoporosis; AqoL = The Assessment of Quality of Life;
EQ-5D = European Quality of Life–5 Dimensions; SF-36 = Short Form 36 General Health Survey (MCS =mental component score, PCS = physical
component score); SOF-ADL = Study of Osteoporotic Fractures-Activities of Daily Living
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back pain. It is designed to assess only physical disability
due to low back pain [35] (scores range from 0 to 23,
with higher numbers indicating worse physical function).
Originally, the scale assessed 12 categories with 24 items
[36], with the modified version including 23 items cover-
ing domains of daily living [31]. The RMDQ was used as
a baseline measure by almost half of the RCTs analyzed
(four of nine studies). Regarding follow-up measure-
ments, the time points ranged from one day to two
months. Three studies chose the same time points, after
one and six months, for follow-up (Fig. 4, Table S1 add-
itional file).
The Oswestry Disability Index (ODI) was developed in
1976 in a specialized referral clinic with a large number
of patients with chronic low back pain [37]. This scale is
a functional measure of HrQOL, which includes six
items in 10 dimensions [38]. However, the ODI was only
collected in one of nine studies [22] (Fig. 4, Table S1
additional file).
The Dallas Pain Questionnaire (DPQ) measures four
categories (16-items) of impairment of daily living due
to chronic low back pain (0% is no pain and 100% is
constant pain) [31, 39]. The DPQ was used in only one
study and at baseline and three-month follow-up [20]
(Fig. 4, Table S1 additional file).
Radiographic imaging
In all studies, VCFs were confirmed by radiological im-
aging. However, only seven of the nine studies analyzed
performed initial imaging by spinal MRI. All follow-up
examinations were performed using conventional radio-
graphs. The most common outcome described was the
occurrence of a new VCF (six of nine RCTs) and the ky-
photic angle above the VCF (two of nine RCTs). Also,
vertebral body height was measured and reported in
three of the nine studies. However, the time points var-
ied between studies. New VCFs were most frequently re-
ported at three and 24months, whereas kyphotic angle
was most frequently measured at 12 months (Fig. 5,
Table S1 additional file).
Others
In addition, other outcome measures were used in the
highly cited RCTs analyzed. In addition to the patient-
reported outcomes described above, opioid use was the
most commonly described outcome parameter (four of
nine studies) (Fig. 6, Table S1 additional file).
Discussion
To the best of our knowledge, this is the first study to
analyze the outcome measurements of frequently cited
Level I studies on VCF treatment. A detailed analysis of
the nine most frequently cited RCTs showed that a var-
iety of questionnaires were used. In addition, there was a
large difference between the survey dates of the ques-
tionnaires. Overall, in all included RCTs, pain (using
VAS-pain) was the most common described outcome
parameter, followed by HrQoL (using EQ-5D) and dis-
ability and function (using RMDQ). Objective outcome
parameters (radiological imaging), however, were de-
scribed less.
Due to the inconsistency in the reported (primary)
outcome parameters of clinical studies, the comparability
of the results and thus also the reliability of meta-
analysis and systematic reviews are made more difficult.
To conduct a high-quality clinical trial, like a level-I
RCT, it is crucial to define and also declare specific out-
come parameters. Moreover, one primary endpoint of a
study should be determined, as it was already recom-
mended in the 1996s’ CONsolidated Standards of
Fig. 4 Overview of the time points at which the different questionnaires from the Disability and Function category were evaluated in the nine
studies analyzed
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Reporting Trials (CONSORT) statement to improve the
reporting of randomised controlled trials [40]. Neverthe-
less, in a cohort of 519 published RCTs in 2000, fewer
than half of the studies reported the primary outcome
[41]. In the nine studies analyzed here, the primary out-
come was reported in six of the nine RCTs.
The most often used outcome parameter in the studies
analyzed was pain assessment by a VAS (or NRS). In this
regard, our results are consistent with a recent system-
atic review of 401 included studies. The authors noted
that the use of the VAS for pain intensity was not only
the most commonly used outcome measure but also has
increased in importance over the past three decades
[42]. Overall, however, it should be kept in mind that
while the VAS pain is an easy-to-use tool for pain
assessment, this is also a highly subjective parameter
that may not specifically indicate back pain.
In the HrQoL category, the most frequently collected
measure was the EQ-5D [28]. This questionnaire is the
most commonly used generic preference-based measure
in clinical trials [43] and has also been cited by other au-
thors as a commonly used outcome measure in low back
pain studies [42]. Besides, the EQ-5D is part of the
Standard Set Low back pain recommended by the Inter-
national Consortium for Health Outcomes Measurement
(ICHOM) [44]. However, a drawback could be that nei-
ther the EQ-5D nor the SF-36 are specific for low back
pain in general and osteoporotic fracture pain in particu-
lar. Thus, a major criticism levelled against the use of
generic HRQoL questionnaires is that these were
Fig. 5 Overview of the time points at which radiographic follow up was evaluated in the nine studies analyzed. VCF Vertebral compression
fracture, MRI = Magnetic Resonance Imaging
Fig. 6 Overview of the various other outcome parameters and the times at which they were evaluated in the nine studies analyzed
Häckel et al. BMC Musculoskeletal Disorders          (2021) 22:579 Page 7 of 10
designed to measure the quality of life across a wide
range of conditions. Therefore, they may not be sensitive
enough to measure a specific difference related to the
disease of interest. Regarding our results, the QUA-
LEFFO is the only vertebral fracture-specific outcome
measure. It was used by only two of the RCTs analyzed
[17, 18]. The other two questionnaires, SOF-ADL and
AqOL, were not specifically designed for outcomes re-
lated to VCF but were at least developed for the elderly
(geriatric) population [33, 34].
Disability and function were measured by most of the
studies reviewed. Moreover, the third most commonly
used outcome parameter overall was the RMDQ, which
was used by four of the nine RCTs reviewed. The
RMDQ has previously been shown to be an easy-to-
administer, well-validated, back pain-specific outcome
measure [45]. Although the ODI has been recommended
as a back pain-specific measure of disability by re-
searchers in this field [46], it was only used by the RCT
conducted by Farrokhi et al. in 2011 [22]. The RMDQ,
however, increasingly used in the early 2000s, lost popu-
larity by 2012 [42].
Although measurement of various parameters using
radiographic imaging has the advantage of being an ob-
jective parameter, it does not necessarily correlate with
the patient’s condition. Despite the fact that there are
several methods of measurement [47], radiological out-
come measures focus mainly on kyphosis angle, reduc-
tion loss, and vertebral body height loss [48]. This is also
consistent with the results of the RCTs that have been
analyzed. Kyphosis angle and vertebral body height were
the most frequently measured parameters. However,
only slightly more than half of the studies reviewed also
described radiological outcome parameters. Especially in
VCFs, it is important to note that the detection of adja-
cent fractures influences the treatment of the underlying
osteoporotic disease. To prevent severe osteoporotic
spinal deformities [49], regular radiological follow-up
should be essential, not only from the surgeon’s point of
view. Particularly little is known about the mid-to-long-
term follow-up of patients who have undergone verte-
bral cement augmentation techniques, and despite our
findings, the question of new and adjacent fractures in
particular, as well as the drug treatment of osteoporosis
itself, needs to become a greater focus of level 1 studies.
For the sake of completeness, all “other” outcome pa-
rameters used should be mentioned here, of which the
use of opioids was the most frequently evaluated. This is
a good objective outcome parameter, although it is
equally based on the subjective perception of pain.
Regarding the planning of follow-up examinations, to
the best of our knowledge, no clear recommendations
exist. In general, the scheduling of included follow-up
examinations should have a pragmatic approach [50],
e.g., following the standard follow-up protocol of the
clinic. In the studies reviewed here, 1 week, 1, 6, 12, and
24months were the most commonly set time points for
follow-up.
Our study has limitations. Only nine RCTs met our in-
clusion criteria, biasing the results of our study [51].
Nonetheless, the included studies were high-quality level
I studies that also had a high number of citations. An-
other limitation is, that we only used one database: The
‘Web of Science Core Collection’. W decided to use this
database because it has been in existence since 1997 and
is the world’s leading citation database. Moreover, it has
been shown that for health sciences and medicine, the
overlap of citations between Web of Science, Scopus and
Google Schoolar is 91–95% [52]. Overall, we think that
this extra effort would not outweigh the benefit. In
addition, there is a possibility that some key outcome
parameters may be overestimated, while others may be
missing. Overall, the objective of this study, however,
was to provide guidance for the design of future clinical
trials and therefore focused on only a few, but highly in-
fluential, articles. All studies analyzed were published be-
tween 2009 and 2011, so age does not translate into
higher citation density. As Aksnes et al. showed, even
for highly cited articles, there is a decrease in citations
starting five years after publication [53]. The citation
rate is probably influenced by the number of authors in-
volved and the breadth of the research field [53–55].
Methodological consistency seems to ensure a high cit-
ation rate [56]. Another limitation is that we cannot say
whether or not there is an influence of the selected out-
come parameters on the study result. However, the pri-
mary aim of this study was not to perform a meta-
analysis but to reflect the conclusions of highly cited in-
fluential studies, which deal with the treatment of VCFs
as this has already been done by Buchbinder [11] and
Anderson et al. [57]. Because of the relationship between
the research question and citation density, the ISI Web
of Knowledge database was used exclusively because it is
the only source for obtaining accurate citation informa-
tion. Although we conducted a comprehensive data col-
lection, we cannot exclude the possibility of missing
articles, so this is another limitation of our study. The
results of our study should help clinicians and re-
searchers select appropriate outcome measures to con-
duct high-quality, comparable studies on the treatment
of VCFs. As a consequence of our systematic literature
review, it can be recommended to focus on the following
outcome parameters when planning future clinical trials:
EQ-5D (included the VAS pain), RMDQ, opioid use and
a radiographic outcome Nevertheless, further research
must address the question of HRQoL scores are suffi-
cient to adequately address the outcome of interven-
tional procedures in traumatic fracture situations.
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Conclusion
With our study, we demonstrated that a large inconsist-
ency exists between outcome measures in highly cited
Level I studies of VCF treatment. Pain (VAS), followed
by HrQoL (EQ-5D) and disability and function (RMDQ),
opioid use, and radiological outcome (kyphotic angle,
VBH, and new VCFs) were the most commonly used
outcome parameters and should be considered when de-
fining the outcome parameters of a study. Consensus on
outcome parameters may improve the relevance of a
study and for further comparisons in meta-analyses.
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